Tan AR, Im SA, Mattar A, Colomer R, et al. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection
plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised,
open-label, multicentre, non-inferiority, phase 3 study. Lancet Oncol 2021;22:85-97.
PMID: 33357420